M0 Prostate Cancer VL

First presentation of SPARTAN - a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) - Eric Small

Details
(Length of Presentation: 23 min) The first presentation of a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC), called SPARTAN is provided here. Eric Small presents the SPARTAN trial first data analysis including the background, methods, primary end points, time to metastasis, progress...

M0 CRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.

Details
(Length of Discussion: 16 min) Fred Saad and Alicia Morgans discuss results from A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER), as well as the endpoint of metastases free survival (MFS). It is exciting that early tr...

SPARTAN: A Study of Apalutamide in Men with M0 Castration-Resistant Prostate Cancer M0 CRPC) - Alan Bryce

Details
(Length of Presentation and Discussion: 9 minutes) Alan Bryce provides an overview of results from SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer - and the subsequent FDA approval of apalutamide for treatment of men with M0 castration resistant prostate cancer ( M0 CRPC). The presentation includes a review of the data on the primary and se...

Changing the Landscape of nmCRPC - The SPARTAN Trial - Eric Small

Details
(Length of Discussion: 25 min) Professor Eric Small, MD talks with Dr. Neal Shore in a post ASCO GU interview on Dr. Eric Small’s plenary presentation on the phase three global SPARTAN trial. A landscape changing treatment for patients with non-metastatic castration resistant prostate cancer. The first drug approved by FDA to satisfy an unmet need for nmCRPC or m0 patients. Dr. Eric Small gives an...